{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T04:41:43Z","timestamp":1760762503780,"version":"build-2065373602"},"reference-count":40,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,10,15]]},"DOI":"10.2169\/internalmedicine.5175-24","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T18:09:42Z","timestamp":1744394982000},"page":"2953-2959","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Rituximab plus Modified EPOCH (Etoposide, Vincristine, Doxorubicin, Carboplatin, and Prednisolone) for Transplant-ineligible Relapsed\/Refractory Diffuse Large B-cell Lymphoma"],"prefix":"10.2169","volume":"64","author":[{"given":"Eriko","family":"Fujioka","sequence":"first","affiliation":[{"name":"Department of Hematology, Iizuka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Kiyasu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iizuka Hospital, Japan"},{"name":"Department of Pathology, Kurume University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Yagi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iizuka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Sawabe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iizuka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Oyama","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iizuka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Hoashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iizuka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Tsuda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iizuka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Takamatsu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iizuka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shojiro","family":"Haji","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iizuka Hospital, Japan"},{"name":"Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Yufu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iizuka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youko","family":"Suehiro","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoaki","family":"Shiratsuchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iizuka Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242, 2002.","DOI":"10.1056\/NEJMoa011795"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116: 2040-2045, 2010.","DOI":"10.1182\/blood-2010-03-276246"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Tilly H, Morschhauser F, Sehn LH, et al. The POLARIX study: polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma. Blood 138 (Suppl 2): LBA-1, 2021.","DOI":"10.1182\/blood-2021-154729"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386: 351-363, 2022.","DOI":"10.1056\/NEJMoa2115304"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Poletto S, Novo M, Paruzzo L, Frascione PMM, Vitolo U. Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer Treat Rev 110: 102443, 2022.","DOI":"10.1016\/j.ctrv.2022.102443"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377: 2531-2544, 2017.","DOI":"10.1056\/NEJMoa1707447"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med 384: 842-858, 2021.","DOI":"10.1056\/NEJMra2027612"},{"key":"8","unstructured":"8. Kozuru M, Uike N, Yufu Y, et al. Saihatsu nanchisei akusei rinpashu ni taisuru modified EPOCH ryoho. Rinsho to Kenkyu (Jpn J Clin Exp Med) 75: 1630-1636, 1998 (in Japanese)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Tsukamoto Y, Kiyasu J, Choi I, et al. Efficacy and safety of the modified EPOCH regimen (etoposide, vincristine, doxorubicin, carboplatin, and prednisolone) for adult T-cell leukemia\/lymphoma: a multicenter retrospective study. Clin Lymphoma Myeloma Leuk 20: e445-e453, 2020.","DOI":"10.1016\/j.clml.2020.03.008"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989.","DOI":"10.1200\/JCO.1989.7.11.1748"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17: 1244, 1999.","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32: 3059-3068, 2014.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hirakawa T, Yamaguchi H, Yokose N, Gomi S, Inokuchi K, Dan K. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol 89: 897-904, 2010.","DOI":"10.1007\/s00277-010-0956-7"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yamaguchi H, Hirakawa T, Inokuchi K. Importance of relative dose intensity in chemotherapy for diffuse large B-cell lymphoma. J Clin Exp Hematop 51: 1-5, 2011.","DOI":"10.3960\/jslrt.51.1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Zamorano JL, Lancellotti P, Mu\u00f1oz DR, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Kardiol Pol 74: 1193-1233, 2016.","DOI":"10.5603\/KP.2016.0156"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 38: 155-165, 2020.","DOI":"10.1200\/JCO.19.00172"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 22: 1403-1415, 2021.","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"18","unstructured":"18. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 20: 31-42, 2019."},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396: 839-852, 2020.","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 386: 640-654, 2022.","DOI":"10.1056\/NEJMoa2116133"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Sehgal A, Hoda D, Riedell PA, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol 23: 1066-1077, 2022.","DOI":"10.1016\/S1470-2045(22)00339-4"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 387: 2220-2231, 2022.","DOI":"10.1056\/NEJMoa2206913"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol 41: 2238-2247, 2023.","DOI":"10.1200\/JCO.22.01725"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Jermann M, Jost LM, Taverna C, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 15: 511-516, 2004.","DOI":"10.1093\/annonc\/mdh093"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Matsuda S, Suzuki R, Takahashi T, et al. Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data. Int J Hematol 112: 807-816, 2020.","DOI":"10.1007\/s12185-020-02984-w"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol 5: e609-e617, 2018.","DOI":"10.1016\/S2352-3026(18)30177-7"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 99: 2685-2693, 2002.","DOI":"10.1182\/blood.V99.8.2685"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368: 1408-1416, 2013.","DOI":"10.1056\/NEJMoa1214561"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Roschewski M, Dunleavy K, Abramson JS, et al. Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma. J Clin Oncol 38: 2519-2529, 2020.","DOI":"10.1200\/JCO.20.00303"},{"key":"30","unstructured":"30. Bartlett NL, Wilson WH, Jung SH, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial Alliance\/CALGB 50303. J Clin Oncol 37: 1790-1799, 2019."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Cazelles C, Belhadj K, Vellemans H, et al. Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory\/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation. Leuk Lymphoma 62: 2161-2168, 2021.","DOI":"10.1080\/10428194.2021.1901090"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 18: 1363-1368, 2007.","DOI":"10.1093\/annonc\/mdm133"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Corazzelli G, Capobianco G, Arcamone M, et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory\/relapsing B-cell lymphoma. Cancer Chemother Pharmacol 64: 907-916, 2009.","DOI":"10.1007\/s00280-009-0941-9"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica 98: 1726-1731, 2013.","DOI":"10.3324\/haematol.2013.090597"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Gopal AK, Press OW, Shustov AR, et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed\/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma 51: 1523-1529, 2010.","DOI":"10.3109\/10428194.2010.491137"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Moccia AA, Hitz F, Hoskins P, et al. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed\/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. Leuk Lymphoma 58: 324-332, 2017.","DOI":"10.1080\/10428194.2016.1193852"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Sakaeda T, Kadoyama K, Okuno Y. Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations. Int J Med Sci 8: 487-491, 2011.","DOI":"10.7150\/ijms.8.487"},{"key":"38","unstructured":"38. Iacoboni G, Navarro V, Martin-Lopez AA, et al. Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy. J Clin Oncol 42: 205-217, 2024."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Bolen CR, Roy S, Huw L-Y, Hatzi K, Penuel E. Baseline CD4 T cells are associated with improved response to CD20-CD3 bispecifics in lymphoma. Blood 142: 3005, 2023.","DOI":"10.1182\/blood-2023-186771"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. van Dalen EC, van der Pal HJ, Kremer LC. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst Rev 3: CD005008, 2016.","DOI":"10.1002\/14651858.CD005008.pub4"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/20\/64_5175-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T04:27:20Z","timestamp":1760761640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/20\/64_5175-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":40,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5175-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"article-number":"5175-24"}}